-
Technologies
Sections on this page

About

Dr Kate Jarman received her PhD in Biochemistry from the University of Adelaide in 2010. Following this, she moved to Melbourne to undertake a postdoctoral position with Professor Shaun Jackson at The Australian Centre for Blood Diseases (Monash University) studying regulatory mechanisms of platelet function in thrombosis.

She joined the Screening Lab at the Walter and Eliza Hall Institute in 2012 and assumed the role of Deputy Head of Screening in January 2019.

She is experienced in leading all facets of screening projects from assay design, development and execution through to hit validation and hit-to-lead support. Dr Jarman has successfully led projects encompassing diverse targets and technologies involving a range of Walter and Eliza Hall Institute disciplines, as well as external academic and pharmaceutical collaborators.

Publications

Selected publications from Dr Kate Jarman

Farrell A, Dall G, Vandenberg CJ, Shield-Artin K, Kyran EL, Blackmore T, Lim R, Taylor R, Neagle C, Ratnayake G, Tan T, Mouradov D, Hadla A, Jarman K, Beard S, Jarratt A, Penington JS, Wakefield MJ, Papenfuss AT, Scott CL, Barker HE. High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma. Journal of Experimental & Clinical Cancer Research. 2026;:10.1186/s13046-025-03629-8

Su W, Nguyen W, Siddiqui G, Dziekan JM, Marapana D, Penington JS, Mehra S, Razook Z, McCann K, Ngo A, Jarman KE, Barry AE, Papenfuss AT, Gilson PR, Creek DJ, Cowman AF, Sleebs BE, Dans MG. Deconvolution of the On-Target Activity of Plasmepsin V Peptidomimetics in Plasmodium falciparum Parasites. ACS Infectious Diseases. 2025;11(12):10.1021/acsinfecdis.5c00742

Mansouri M, Dans MG, Low Z, Loi K, Jarman KE, Penington JS, Qiu D, Lehane AM, Crespo B, Gamo F, Baud D, Brand S, Jackson PF, Cowman AF, Sleebs BE. Exploration and Characterization of the Antimalarial Activity of Pyrimidine‐2,4‐Diamines for which Resistance is Mediated by the ABCI3 Transporter. ChemMedChem. 2025;:10.1002/cmdc.202500739

Nguyen W, Boulet C, Dans MG, Loi K, Jarman KE, Barnes CBG, Yeo T, Sheth T, Mukherjee P, Chakraborty A, Famodimu MT, Delves MJ, Pollard H, Sutherland CJ, Coyle R, Sevilleno N, Boonyalai N, Lee MCS, Rabie T, Birkholtz L-M, Baud D, Brand S, Chowdury M, de Koning-Ward TF, Fidock DA, Gilson PR, Sleebs BE. Optimization and Characterization of the Antimalarial Activity of N‑Aryl Acetamides that are Susceptible to Mutations in ROM8 and CSC1. Journal of Medicinal Chemistry. 2025;68(15):10.1021/acs.jmedchem.5c01471

Hodder AN, Sleebs BE, Adams G, Rezazadeh S, Ngo A, Jarman K, Scally S, Czabotar P, Wang H, McCauley JA, Olsen DB, Cowman AF. Structure–activity analysis of imino‐pyrimidinone‐fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors. The FEBS Journal. 2025;292(11):10.1111/febs.70038

Pan B, Mountford SJ, Kiso M, Anderson DE, Papadakis G, Jarman KE, Tilmanis DR, Maher B, Tran T, Shortt J, Yamayoshi S, Kawaoka Y, Thompson PE, Greenall SA, Warner N. Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus. Communications Medicine. 2025;5(1):10.1038/s43856-025-00863-1

Awalt JK, Ooi ZK, Ashton TD, Mansouri M, Calic PPS, Zhou Q, Vasanthan S, Lee S, Loi K, Jarman KE, Penington JS, Qiu D, Zhang X, Lehane AM, Mao EY, Gancheva MR, Wilson DW, Giannangelo C, MacRaild CA, Creek DJ, Yeo T, Sheth T, Fidock DA, Churchyard A, Baum J, Famodimu MT, Delves MJ, Kristan M, Stewart L, Sutherland CJ, Coyle R, Jagoe H, Lee MCS, Chowdury M, de Koning-Ward TF, Baud D, Brand S, Jackson PF, Cowman AF, Dans MG, Sleebs BE. Optimization and Characterization of N‑Acetamide Indoles as Antimalarials That Target PfATP4. Journal of Medicinal Chemistry. 2025;68(8):10.1021/acs.jmedchem.5c00614

Ashton TD, Calic PPS, Dans MG, Ooi ZK, Zhou Q, Loi K, Jarman KE, Palandri J, Qiu D, Lehane AM, Maity B, De N, Famodimu MT, Delves MJ, Mao EY, Gancheva MR, Wilson DW, Chowdury M, de Koning‐Ward TF, Baud D, Brand S, Jackson PF, Cowman AF, Sleebs BE. Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4. ChemMedChem. 2024;19(24):10.1002/cmdc.202400549

Awalt JK, Su W, Nguyen W, Loi K, Jarman KE, Penington JS, Ramesh S, Fairhurst KJ, Yeo T, Park H, Uhlemann A-C, Maity BC, De N, Mukherjee P, Chakraborty A, Churchyard A, Famodimu MT, Delves MJ, Baum J, Mittal N, Winzeler EA, Papenfuss AT, Chowdury M, de Koning-Ward TF, Maier AG, van Dooren GG, Baud D, Brand S, Fidock DA, Jackson PF, Cowman AF, Dans MG, Sleebs BE. Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome b. European Journal of Medicinal Chemistry. 2024;280:10.1016/j.ejmech.2024.116921

Calic PPS, Ashton TD, Mansouri M, Loi K, Jarman KE, Qiu D, Lehane AM, Roy S, Rao GP, Maity B, Wittlin S, Crespo B, Gamo F-J, Deni I, Fidock DA, Chowdury M, de Koning-Ward TF, Cowman AF, Jackson PF, Baud D, Brand S, Laleu B, Sleebs BE. Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3. European Journal of Medicinal Chemistry. 2024;276:10.1016/j.ejmech.2024.116677

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.